Literature DB >> 16640960

The ligand/RAGE axis: lighting the fuse and igniting vascular stress.

Shi Fang Yan1, Yoshifumi Naka, Barry I Hudson, Kevan Herold, Shi Du Yan, Ravichandran Ramasamy, Ann Marie Schmidt.   

Abstract

Vascular inflammation contributes critically to the initiation and progression of atherosclerosis. These processes are accelerated in hyperglycemia and play key roles in the increased incidence and severity of myocardial infarction and stroke observed in diabetes. Evidence suggests that the ligands of the receptor for advanced glycation endproducts (RAGE), a multiligand member of the immunoglobulin superfamily, interact with this receptor to play important roles in both early development and progression of atherosclerosis and vascular inflammation. Studies in animal models of vascular injury underscored the potent impact of RAGE blockade; administration of ligand-binding decoys of RAGE or antibodies to the receptor reduced the consequences of diabetes, hyperlipidemia, and physical injury to the vessel wall. This review focuses on the ligand repertoire of RAGE, the impact of ligand-RAGE interaction, and the potent effect of RAGE blockade in rodent models of vascular injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16640960     DOI: 10.1007/s11883-006-0078-9

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  50 in total

1.  Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis.

Authors:  S D Yan; H Zhu; A Zhu; A Golabek; H Du; A Roher; J Yu; C Soto; A M Schmidt; D Stern; M Kindy
Journal:  Nat Med       Date:  2000-06       Impact factor: 53.440

2.  Study of the -429 T/C and -374 T/A receptor for advanced glycation end products promoter polymorphisms in diabetic and nondiabetic subjects with macrovascular disease.

Authors:  B I Hudson; M H Stickland; T S Futers; P J Grant
Journal:  Diabetes Care       Date:  2001-11       Impact factor: 19.112

3.  Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.

Authors:  A Taguchi; D C Blood; G del Toro; A Canet; D C Lee; W Qu; N Tanji; Y Lu; E Lalla; C Fu; M A Hofmann; T Kislinger; M Ingram; A Lu; H Tanaka; O Hori; S Ogawa; D M Stern; A M Schmidt
Journal:  Nature       Date:  2000-05-18       Impact factor: 49.962

4.  beta(2)-Microglobulin modified with advanced glycation end products delays monocyte apoptosis.

Authors:  F F Hou; T Miyata; J Boyce; Q Yuan; G M Chertow; J Kay; A M Schmidt; W F Owen
Journal:  Kidney Int       Date:  2001-03       Impact factor: 10.612

5.  Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.

Authors:  Colomba Falcone; Enzo Emanuele; Angela D'Angelo; Maria P Buzzi; Chiara Belvito; Mariaclara Cuccia; Diego Geroldi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-02-24       Impact factor: 8.311

6.  Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis.

Authors:  Masataka Sata; Akio Saiura; Atsushi Kunisato; Akihiro Tojo; Seiji Okada; Takeshi Tokuhisa; Hisamaru Hirai; Masatoshi Makuuchi; Yasunobu Hirata; Ryozo Nagai
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

7.  The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients.

Authors:  Kim Pettersson-Fernholm; Carol Forsblom; Barry I Hudson; Markus Perola; Peter J Grant; Per-Henrik Groop
Journal:  Diabetes       Date:  2003-03       Impact factor: 9.461

8.  IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism.

Authors:  Beatriz Rendon-Mitchell; Mahendar Ochani; Jianhua Li; Jialian Han; Hong Wang; Huan Yang; Seenu Susarla; Christopher Czura; Robert A Mitchell; Guoqian Chen; Andrew E Sama; Kevin J Tracey; Haichao Wang
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

9.  RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response.

Authors:  M A Hofmann; S Drury; B I Hudson; M R Gleason; W Qu; Y Lu; E Lalla; S Chitnis; J Monteiro; M H Stickland; L G Bucciarelli; B Moser; G Moxley; S Itescu; P J Grant; P K Gregersen; D M Stern; A M Schmidt
Journal:  Genes Immun       Date:  2002-05       Impact factor: 2.676

10.  RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB.

Authors:  Guellue Cataldegirmen; Shan Zeng; Nikki Feirt; Nikalesh Ippagunta; Hao Dun; Wu Qu; Yan Lu; Ling Ling Rong; Marion A Hofmann; Thomas Kislinger; Sophia I Pachydaki; Daniel G Jenkins; Alan Weinberg; Jay Lefkowitch; Xavier Rogiers; Shi Fang Yan; Ann Marie Schmidt; Jean C Emond
Journal:  J Exp Med       Date:  2005-02-07       Impact factor: 14.307

View more
  4 in total

1.  IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies.

Authors:  Aimalie L Hardaway; Izabela Podgorski
Journal:  Future Med Chem       Date:  2013-06       Impact factor: 3.808

2.  Effects of glycation of the model food allergen ovalbumin on antigen uptake and presentation by human dendritic cells.

Authors:  Tamara Hilmenyuk; Iris Bellinghausen; Bärbel Heydenreich; Anne Ilchmann; Masako Toda; Stephan Grabbe; Joachim Saloga
Journal:  Immunology       Date:  2009-11-16       Impact factor: 7.397

Review 3.  Is RAGE still a therapeutic target for Alzheimer's disease?

Authors:  Richard J Deane
Journal:  Future Med Chem       Date:  2012-05       Impact factor: 3.808

4.  Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimer's Disease.

Authors:  L Arab; R Sadeghi; D G Walker; L-F Lue; M N Sabbagh
Journal:  Curr Neuropharmacol       Date:  2011-12       Impact factor: 7.363

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.